WHO ICTRP trial
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult…
NCT05126576 · NIH Clinical Trials · Not recruiting
Key facts
| Trial ID | NCT05126576 |
|---|---|
| Public title | Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 |
| Scientific title | A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19 |
| Acronym | MORNINGSKY |
| Primary sponsor | Hoffmann-La Roche |
| Registry | NIH Clinical Trials |
| Recruitment status | Not recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Argentina;Belgium;Brazil;Denmark;France;Germany;Italy;Japan;Mexico;Portugal;Romania;South Africa;Switzerland;Turkey;Ukraine;Argentina;Belgium;Brazil;Denmark;France;Germany;Italy;Japan;Mexico;Portugal… |
| Conditions | COVID-19 |
| Interventions | Drug: RO7496998;Drug: Placebo |
| Registration date | Nov 17, 2021 |
| Target size | 1386 |
| Secondary IDs | 2020-005759-18;CV43043 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: